Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma

The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Kevin Y, Wu, Shenhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346105/
https://www.ncbi.nlm.nih.gov/pubmed/25734007
http://dx.doi.org/10.1186/s40364-015-0030-7
_version_ 1782359685081333760
author Xu, Kevin Y
Wu, Shenhong
author_facet Xu, Kevin Y
Wu, Shenhong
author_sort Xu, Kevin Y
collection PubMed
description The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective of this review is to describe new developments in targeted treatments and immunotherapies for patients with both clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging avenues of RCC treatment that show considerable promise.
format Online
Article
Text
id pubmed-4346105
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43461052015-03-03 Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma Xu, Kevin Y Wu, Shenhong Biomark Res Review The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective of this review is to describe new developments in targeted treatments and immunotherapies for patients with both clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging avenues of RCC treatment that show considerable promise. BioMed Central 2015-03-02 /pmc/articles/PMC4346105/ /pubmed/25734007 http://dx.doi.org/10.1186/s40364-015-0030-7 Text en © Xu and Wu; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Xu, Kevin Y
Wu, Shenhong
Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
title Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
title_full Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
title_fullStr Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
title_full_unstemmed Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
title_short Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
title_sort update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346105/
https://www.ncbi.nlm.nih.gov/pubmed/25734007
http://dx.doi.org/10.1186/s40364-015-0030-7
work_keys_str_mv AT xukeviny updateonthetreatmentofmetastaticclearcellandnonclearcellrenalcellcarcinoma
AT wushenhong updateonthetreatmentofmetastaticclearcellandnonclearcellrenalcellcarcinoma

Ejemplares similares